Thromboembolic Risk: Reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease. Resume anticoagulant therapy as soon as medically appropriate.
Re-elevation of Coagulation Parameters: In patients with elevated coagulation parameters and reappearance of clinically relevant bleeding or requiring a second emergency surgery/urgent procedure, an additional 5 g dose of PRAXBIND may be considered.
Hypersensitivity reactions: Discontinue administration and evaluate.
Risks of Serious Adverse Reactions in Patients with Hereditary Fructose Intolerance due to Sorbitol Excipient: Patients with hereditary fructose intolerance may be at risk of adverse reactions.
In healthy volunteers, the most frequently reported adverse reactions in ≥5% of subjects treated with<unk>  was headache
In patients, the most frequently reported adverse reactions in ≥5% of patients treated with<unk>  were hypokalemia, delirium, constipation, pyrexia, and pneumonia
Idarucizumab
Tocilizumab
Sotrovimab
Obiltoxaximab
Sarilumab
Raxibacumab
Rituximab
Baricitinib